Rein Therapeutics (NASDAQ:RNTX) Trading Down 1.8% - Time to Sell?

Key Points

• Rein Therapeutics (NASDAQ:RNTX) fell 1.8% on Friday, trading as low as $0.941 and closing near $0.98 on lighter-than-average volume.
• Analyst sentiment is mixed: HC Wainwright cut its price target to $8 but kept a buy rating, while Wall Street Zen upgraded to hold and Weiss Ratings reiterated a sell. The consensus rating remains Hold with an average target price of $7.00.
• The clinical-stage biotech beat its last quarterly EPS estimate, reporting a loss of $0.19 versus expectations for a $0.49 loss, while its lead candidate RT-101 continues early-phase trials in solid tumors.

Shares of Rein Therapeutics Inc. (NASDAQ:RNTX - Get Free Report) were down 1.8% on Friday . The stock traded as low as $0.9410 and last traded at $0.98. 148,430 shares changed hands during trading, a decline of 74% from the average session volume of 579,701 shares. The stock had previously closed at $0.9978.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. HC Wainwright decreased their price target on shares of Rein Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a report on Monday, June 1st. Wall Street Zen upgraded shares of Rein Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 6th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Rein Therapeutics in a report on Friday, June 26th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Rein Therapeutics has an average rating of "Hold" and a consensus target price of $7.00.

Rein Therapeutics Price Performance

The stock has a fifty day moving average price of $1.02 and a two-hundred day moving average price of $1.21. The company has a market cap of $83.83 million, a P/E ratio of -0.52 and a beta of 1.35.

Rein Therapeutics (NASDAQ:RNTX - Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.30. As a group, analysts forecast that Rein Therapeutics Inc. will post -0.53 earnings per share for the current year.

Institutional Investors Weigh In On Rein Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of RNTX. Voss Capital LP boosted its holdings in shares of Rein Therapeutics by 86.0% in the third quarter. Voss Capital LP now owns 2,666,532 shares of the company's stock valued at $3,053,000 after acquiring an additional 1,232,846 shares in the last quarter. State Street Corp lifted its position in Rein Therapeutics by 374.3% in the fourth quarter. State Street Corp now owns 75,904 shares of the company's stock worth $88,000 after purchasing an additional 59,900 shares during the period. Geode Capital Management LLC boosted its stake in Rein Therapeutics by 15.1% during the 4th quarter. Geode Capital Management LLC now owns 284,555 shares of the company's stock valued at $330,000 after purchasing an additional 37,244 shares in the last quarter. Cable Car Capital LP acquired a new position in shares of Rein Therapeutics during the 2nd quarter valued at $588,000. Finally, Prosight Management LP raised its stake in shares of Rein Therapeutics by 32.7% in the 3rd quarter. Prosight Management LP now owns 567,898 shares of the company's stock worth $650,000 after buying an additional 139,979 shares in the last quarter. 90.89% of the stock is currently owned by institutional investors.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company's core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.